Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from BioInvent International AB ( (SE:BINV) ).
BioInvent International AB has presented promising early Phase 2a data for its BI-1808 monotherapy in treating cutaneous T-cell lymphoma (CTCL) at the ASH 2025 meeting. The trial showed a 46% objective response rate and a 92% disease control rate among evaluable patients, with evidence of immune activation. The company is also exploring BI-1808 in combination with pembrolizumab for solid tumors, positioning itself for significant market opportunities with Fast Track and Orphan Drug designations.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK28.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a biotechnology company specializing in the discovery and development of novel antibodies for cancer immunotherapy. The company focuses on creating innovative treatments for various types of cancer, with a particular emphasis on T-cell lymphomas.
YTD Price Performance: -25.06%
Average Trading Volume: 98,390
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.9B
For an in-depth examination of BINV stock, go to TipRanks’ Overview page.